Abstract
ABSTRACT BACKGROUND The predictive value of advanced lung cancer inflammation index (ALI) in all-cause mortality and cardiovascular mortality among hypertensive patients has not been thoroughly investigated. METHOD AND RESULTS A total of 2805 hypertensive patients from the National Health and Nutrition Examination Surveys from 2005-2006 to 2017-2018 were ultimately included in the analysis. Over the study period, participants were followed up for an average of 57.6 months, during which 311 deaths occurred, with 89 deaths attributed to cardiovascular causes. Survey-weighted restricted cubic spline (RCS) analysis revealed a nonlinear negative correlation between ALI and both all-cause and cardiovascular mortality among hypertensive patients. Survey-weighted Cox proportional hazards models revealed that in the highest ALI quartile experienced a 53.8% reduction in all-cause mortality and an 83.5% reduction in cardiovascular mortality compared with those in the lowest quartile. Survey-weighted Kaplan-Meier survival analysis also revealed that the all-cause mortality and cardiovascular mortality of hypertensive patients in the high ALI group were significantly lower than those in the low ALI group. Time-dependent ROC curves were used to assess the accuracy of survival outcomes and the area under the curve (AUC) values for the ability of ALI to predict all-cause mortality at 1, 3, and 5 years among hypertensive patients were 0.772, 0.672, and 0.634, respectively, whereas the AUC values for predicting cardiovascular mortality were 0.735, 0.760, and 0.723, respectively. CONCLUSIONS ALI can be a valuable and effective tool for identifying high-risk hypertensive patients and guiding targeted interventions.
Competing Interest Statement
The authors have declared no competing interest.
Clinical Trial
All procedures adhered to the principles outlined in the Declaration of Helsinki, and NHANES has secured personal informed and written consent from every participant, ensuring their awareness and agreement in the study.
Clinical Protocols
http://www.cdc.gov/nchs/nhanes/index.htm
Funding Statement
This work was supported by a grant from the Health Commission of Hubei Province Funded Project (grant number W2023F043).
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
http://www.cdc.gov/nchs/nhanes/index.htm
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data Availability
All data are publicly available and can be accessed at the NHANES (the National Health and Nutrition Examination Survey) website (http://www.cdc.gov/nchs/nhanes/index.htm). Relevant DecisionLinnc and R code is available upon reasonable request to the corresponding author. The first author had full access to all data in the study and takes responsibility for its integrity and the data analysis.
https://www.who.int/data/gho/publications/world-health-statistics.
